An 80% ethanolic extract of Gloriosa superba L. seeds (glory lily, Colchicaceae), as well as a colchicine-poor/colchicoside-rich extract, were shown to exhibit antitumor activity in a murine model for pancreatic cancer. Phytochemical investigations of the 80% ethanolic extract led to the identification of colchicine, 3-O-demethylcolchicine, and colchicoside. The objective of this work was to develop and validate a high performance liquid chromatographic analytical method according to the ICH guidelines for the quantification of these constituents. The calibration model appeared to be linear, ranging from 2.1 µg/mL to 41.9 µg/mL. The method was shown to be precise with respect to time (RSD% of 3.1% for colchicine, 2.9% for 3-O-demethylcolchicine, and 4.7% for colchicoside, 3 days, n = 6) and with respect to the concentration (RSD% of 2.9% for colchicine, 3.0% for 3-O-demethylcolchicine and 4.1% for colchicoside, 3 levels, n = 6). The recovery of colchicine resulted in a mean recovery of 100.02% with a RSD% of 2.1%. The correction factors for colchicoside and 3-O-demethylcolchicine were determined as 1.94 and 1.20, respectively. The total amount of colchicine and colchicine derivatives found in the crude extract of G. superba was 4.6% (m/m) expressed as colchicine and the overall mean of colchicine found in the crude extract was 2.8% (m/m). By using the correction factors, the other constituents of the crude extract could also be quantified, and it was found to contain 1.5% (m/m) colchicoside and 1.3% (m/m) 3-O-demethylcolchicine.
Gloriosa superba L. (Colchicaceae), commonly called glory lily, is native to tropical Africa, south-eastern Asia and India, and is now widely cultivated throughout the world as an ornamental plant [1] . The tubers contain colchicine, a well-known medicine against gout. Colchicine has antimitotic properties and has been used in the treatment of cancer [2, 3] . It also contains other, very similar alkaloids such as demethylcolchicines and the glycoside colchicoside [4] [5] [6] . Recently, antitumor activity was demonstrated for a G. superba extract and a colchicine-poor / colchicoside-rich extract was active in a murine model for pancreatic cancer [7, 8] . Therefore, it was necessary to prepare quantified extracts with known levels of colchicine and colchicine derivatives, and an analytical method had to be developed and validated [9] . Ondra et al. published a high-performance liquid chromatographic method for the determination of the colchicine derivatives found in different Colchicum spp. plants [10] . Another HPLC-UV method was described by Chitra and Rajamani for the quantitative analysis of the active components of G. superba tubers [11] . The European Pharmacopoeia also describes a liquid chromatographic method to determine the metabolites related to colchicine [12] . Recently a RP-HPLC method was reported to compare the colchicine and colchicoside content of seeds of G. superba and Colchicum speciosum [13] . These methods were used as a starting point to optimize a new simplified method, focusing on the combined quantification of the three main compounds found in the 80% EtOH extract of the seeds of G. superba and the colchicinepoor/colchicoside-rich extract using HPLC-UV.
G. superba seeds were phytochemically investigated using chromatographic and spectroscopic techniques. The HPLC analyses revealed three main compounds in the 80% ethanolic extract, which were isolated and identified as colchicoside, 3-O-demethylcolchicine and colchicine ( Figure 1) . Because of the known toxicity of colchicine, a colchicine-poor / colchicoside-rich extract was prepared through liquid-liquid partition. By acidifying the aqueous phase and consecutive extraction steps with diethyl ether and methylene chloride, most of the colchicine was removed and a colchicine-poor/colchicoside-rich extract was created. An HPLC method was developed and validated for both extracts.
Firstly, sample preparation was optimized. Methanol, water, and 50% aqueous methanol were used to dissolve the 80% ethanolic extract (100 mg) and the reference material colchicine. The samples were ultrasonicated and then diluted. Every time a parameter was tested, all other parameters were kept the same. The reference material dissolved immediately in all solvents. However, the solubility of the crude extract in water and 50% aqueous methanol was not adequate compared with methanol. Methanol was therefore chosen to dissolve the extract, but because of the asymmetrical peak shape, frequently caused by injecting a 100% methanol solution, it was necessary to dilute the solution with water resulting in a lower percentage of methanol. The dissolved extract was diluted in 50% methanol. Also the ultrasonication time was optimized. The extract was dissolved in 100% methanol and then ultrasonicated for 5, 10, 15, and 30 min. The area under the curve was improved by using a longer sonication time, but no additional benefits were observed by sonicating longer than 15 min. Therefore, in the final method a sonication time of 15 min was used.
In the final step of method development it was established whether the method was also applicable in other ranges, usually 50% and 150% of the amount used, i.e. 100 mg in 20 mL MeOH. Since analyzing 50 mg and 150 mg of the extract using the same conditions yielded results that were in good agreement, this sample preparation was selected.
Different chromatographic conditions have been described in the literature. In the LC-UV method of Chitra and Rajamani an isocratic system consisting of water and acetonitrile (70:30) was used [10, 11] . An isocratic system consisting of phosphate buffer and methanol was also described in the European Pharmacopoeia (Ph. Eur.). These systems were evaluated, but did not provide sufficient peak resolution for the crude extract. Therefore, a general gradient was tested, which was 0 min, 5% B; 5 min, 5% B; 55 min, 100% B and 60 min, 100% B, with mobile phase A being water containing trifluoroacetic acid (TFA) (0.05%) and mobile phase B being acetonitrile,. The gradient was adjusted in order to shorten the total run time, thus reducing the solvent consumption, but taking into account not to decrease the quality of the separation. A good separation was reached with the gradient 0 min, 10% B; 5 min, 10% B; 25 min, 40% B; 35 min, 100% B; 40 min, 100% B. In order to see if the acid had an added value to the peak shape, different acids and water without acid were tested. It was concluded that the acids did not improve the peak shape. The flow rate and column temperature were set at 1.0 mL/min and 25°C. Different flow rates and column temperatures were also tested, but none of the tested parameters gave better results. Two different HPLC columns were tested, a Grace Apollo 5µm C 18 and a Phenomenex Luna 5 µm C 18 . Better separation was obtained with the Luna column and therefore this column was chosen. Once an acceptable chromatogram was achieved, a suitable detection wavelength was chosen using the diode-array detector (DAD). The wavelength was set at the UV absorption maximum of the three main compounds, which is 245 nm.
Validation
Calibration model: The linearity for colchicine was investigated and the regression line was plotted in Figure 2 . The least squares line was evaluated by calculating the correlation coefficient and the residuals, which were plotted in Figure 3 . Graphical examination of the regression curve and the residual plot proved that the method was linear for colchicine. The residuals were randomly scattered and showed a condition of homoscedasticity. The highest residual corresponded to 1.5% of the signal of the 100% concentration, which is within the limit for LC-UV of 5%. The intercept, slope and their standard errors were calculated. The intercept was evaluated by calculating the confidence interval and checking whether the origin, point (0, 0), was included. The slope of the calibration curve was inspected by means of the Student's t-test. An analysis of variances (ANOVA) lack of fit F-test was performed and the quality coefficient was calculated. All of these results are summarized in Table 1 . The origin fell within the calibration curve, since zero was included in the 95% confidence interval. The slope of the curve was significant; t calc (764.56) was higher than t crit (2.10). The correlation coefficient was approved since it was at least 0.999. The ANOVA showed that F calc (5.20) was lower than F crit (6.94 ) . The quality coefficient was also lower than 2.50%. Thus, it can be concluded that the method was linear within the range 0.0021 to 0.0419 mg/mL. Although a single-point calibration is justified, since the origin fell within the calibration curve, a calibration curve with the highest, lowest and 100% concentration was constructed each time an analysis was performed, because of the very broad range of the compounds in the extract. Precision: In order to evaluate the repeatability, six separate samples were analyzed on the same day. Every sample was injected once. The calibration curve of the reference solutions was used to determine the amount of colchicine. These solutions were injected at the beginning and the end of the sequence, so each solution/concentration level was injected in duplicate. For the intermediate precision on different days six separate samples (100% or 100 mg) were analyzed on the same day, and this was repeated on two consecutive days. Every sample was injected once. The reference solutions for the calibration curve used to determine the amount of colchicine were freshly prepared on each day and also injected at the beginning and the end of the sequence. For the intermediate precision at different concentration levels, six samples with half the amount (50% or 50 mg) and six samples with higher amount (150% or 150 mg) were analyzed using the same method.
The amount of the individual compounds was calculated using the peak areas of the samples and the calibration curve. The mean, the standard deviation and the relative standard deviation for each compound, for each day and each concentration level were calculated and are summarized in Table 2 . The homogeneity of the variances of the results from the different days and different concentration levels were tested, prior to conducting an ANOVA,
C o l c h i c i n e
Range (mg/mL) 0.0021 -0.0419
Number of standards 10
Intercept ± standard error - by performing Cochran's test. The calculated Cochran value C calc was compared with the critical value at the 5% level of confidence C crit . The results are shown in Table 3 . C calc was smaller than C crit , therefore the variances of the different days and different concentration levels were of similar magnitude and an ANOVA (one way, single factor, α = 0.05) was performed. For the evaluation of the repeatability and intermediate precision, the within-day and within-level relative standard deviation (RSD% within ) and the between-day and between-level relative standard deviation (RSD% between ) were calculated. All these results are summarized in Table 2 . The results indicated that the developed method showed acceptable precision. From the statistical point of view, the ANOVA ( Capistrano I et al.
concentration levels for 3-O-demethylcolchicine (F calc was smaller than F crit ). For the two other alkaloids (colchicine and colchicoside) F calc was bigger than F crit , the RSD% within and RSD% between were also higher than the limit set by Horwitz [14, 15] , but still smaller than 5%, which was an acceptable limit.
Therefore, the method was considered to be precise for the three compounds with respect to time and concentration. After graphical inspection of the results (Figure 4) , the same conclusion could be made that no dependency on time or concentration of the results could be observed.
Accuracy:
The accuracy for colchicine was investigated using the standard addition method, and was tested on at least three concentration levels in triplicate. The recovery percentage was calculated for each of the individually prepared samples, and the content of colchicine is shown in Table 4 . The mean recovery, the RSD% and the 95% confidence interval were calculated. A mean recovery of 100.02% with a RSD% of 2.17% was found. The confidence interval ranged from 98.36% to 101.69%. Since 100% was included in the 95% confidence interval, the recovery percentage found was not significantly different from 100%, thus the method can be considered to be accurate for colchicine. In order to check whether the recovery experiment was performed with the same precision as previous experiments, the values of the accuracy were compared with those of the precision in a F-test. F calc (1.57) was smaller than F crit (2.65) and it was then concluded that the recovery experiment was performed with the same precision. The recovery was also plotted in function of the different concentration levels and shown in Figure 5 . 
Specificity:
The specificity of the method was determined by investigating the peak purity of the three compounds (colchicoside, 3-O-demethylcolchicine, and colchicine) in the crude extract using HPLC-DAD.
Correction factor: The amount of the colchicine derivatives can now be quantified using the validated method, but is still expressed as colchicine equivalents. In order to determine the exact amount of the individual colchicine derivatives present in the crude extract, suitable reference materials were necessary. Colchicoside and 3-Odemethylcolchicine of known purity would be the reference materials of choice, but they were either not commercially available or very expensive. To overcome this, a secondary standard was used. For these two alkaloids, colchicine would be the ideal secondary standard, considering that they are derivatives of colchicine. The difference in detector response between both standards needed to be taken into account using a correction factor, which needed to be determined and validated. Therefore sufficient amounts of colchicoside and 3-O-demethylcolchicine were isolated using semi-preparative HPLC.
Validation of the correction factor Linearity of the primary standard: The linearity of colchicoside and 3-O-demethylcolchicine was investigated and regression analysis was performed. The intercept, slope and standard errors are shown in Table 5 and the calibration curves were constructed ( Figure 6 ). The residuals were calculated and plotted ( Figure 7 ). The graphical examination of the calibration curves and the residuals proved that the method was linear, the residuals were randomly scattered, and that the calibration model showed a condition of homoscedasticity. The highest residual corresponded to 1.75% of the signal of the 100% concentration for colchicoside and 1.11% for 3-O-demethylcolchicine, which were both within the limit for LC-UV of 5%. The confidence interval of the intercept was calculated; the slope of the calibration curve was evaluated by means of the Student's t-test and the correlation factor was calculated. An ANOVA was performed and the quality coefficient was calculated. All of the results are shown in Table 5 .
For colchicoside the (0,0) point fell within the 95% confidence interval and the slope of the curve was significant. T calc (763.2) was higher than t crit (2.1). The correlation coefficient was at least 0.99. The ANOVA lack of fit showed that F calc (2.6) is lower than F crit (6.9) and the quality coefficient (0.43%) was lower than 2.50%. All of these data resulted in a calibration curve for colchicoside that was found to be linear within the range of 0.002 to 0.041 mg/mL. For 3-O-demethylcolchicine the point (0,0) fell within the 95% confidence interval and the slope of the curve was significant. T calc (984.7) was higher than t crit (2.1). The correlation coefficient was also at least 0.99. The ANOVA lack of fit showed that F calc (13.8) is higher than F crit (6.9) suggesting that there is a lack of linear fit. This is sometimes the case when the pure error between duplicates are small compared with the lack of fit due to the use of an automatic injector, but since the quality coefficient (0.29%) was lower than 2.50%, the calibration curve for 3-O-demethylcolchicine was linear within the range of 0.002 to 0.043 mg/mL. 
Precision of the response correction factor:
For the determination and validation of the correction factor both primary standard (colchicoside and 3-O-demethylcolchicine) and secondary standard (colchicine) were injected on three different days. The correction factor for the response was calculated for every injection considering the concentrations and peak areas of the primary and secondary standards. For colchicoside, the mean correction factors for each day were 1.93 (day 1), 1.91 (day 2), 1.97 (day 3) and the overall mean correction factor was 1.94. An ANOVA (one way, single factor, α=0.05) was performed on all the correction factors obtained on the different days. By means of the F-test the difference between the results of the different days were investigated. The F calc was 79.5, which is higher than the F crit (3.68), but the RSD% between days, is 1.71%, and smaller than 5%, so the mean correction factor for the response was applicable for the whole range of the method. For 3-O-demethylcolchicine, the mean correction factors for each day were 1.19 (day 1), 1.17 (day 2), 1.25 (day 3) and the overall mean correction factor was 1.20. An ANOVA (one way, single factor, α=0.05) was performed on all the correction factors obtained on the different days. By means of the F-test, the difference between the results of the different days was investigated. The F calc was 263.12, which is higher than the F crit (3.68), but the RSD% between days is 3.51%, and smaller than 5%, so the mean correction factor for the response was applicable for the whole range of the method.
Quantification of different batches of the extract
With this new developed and validated method, different batches of plant extract were analyzed. The plant material was extracted in different batches. Not all batches contained the same amount of colchicine and colchicine derivatives. This indicates again the importance of an analytical method to quantify the constituents of a plant extract. Even though the starting plant material is purportedly the same, extraction of the constituents can differ. Therefore, every batch used in this study was quantified using the validated method. The batch used to optimize and validate the method contained 4.62% colchicine and colchicine derivatives expressed as colchicine, and the overall mean of colchicine found in this batch was 2.81%. The individual content of the colchicine derivatives was calculated using the correction factor and resulted in 1.46% of colchicoside and 1.27% of 3-O-demethylcolchicine.
The crude extract used for the in vivo study and the colchicinepoor/colchicoside-rich extract were analyzed using the validated method. The batch used for the in vivo study contained 5.79% of colchicine and colchicine derivatives expressed as colchicine. This batch contained 3.22% colchicine, 2.52% colchicoside, and 1.52% 3-O-demethylcolchicine. The colchicine-poor/colchicoside-rich extract contained 1.61% of colchicine and colchicine derivatives expressed as colchicine, more in particular 0.07% colchicine, 2.26% colchicoside and 0.46% 3-O-demethylcolchicine [7, 8] .
In conclusion, an analytical method for the quantification of the three main constituents of the 80% ethanolic extract of G. superba and a colchicine-poor/colchicoside-rich extract has been optimized and validated. This method quantifies the total amount of colchicine and colchicine derivatives expressed as colchicine. This analytical method was then validated according to the ICH (International Council for Harmonization) guidelines. The calibration curve of colchicine indicated that the model was linear over the range of 0.0021 to 0.0419 mg/mL. The method was shown to be precise with respect to time (RSD% of 3.07% for colchicine, 2.88% for 3-Odemethylcolchicine and 4.74% for colchicoside, 3 days, n = 6) and with respect to the concentration (RSD% of 2.91% for colchicine, 3.04% for 3-O-demethylcolchicine and 4.12% for colchicoside, 3 levels, n = 6). The overall mean of colchicine and colchicine derivatives found in the crude extract of G. superba was 4.62% expressed as colchicine, and the overall mean of colchicine found in the crude extract was 2.81%. The accuracy of the method was investigated by means of the standard addition method in which the recovery of colchicine was tested. This resulted in a mean recovery of 100.02% with a RSD% of 2.17%. Based on these results it can be concluded that the newly optimized method is suitable for its purpose, namely the quantification of the total amount of colchicine derivatives (colchicoside and 3-O-demethylcolchicine) and colchicine in the crude extract of G. superba expressed as colchicine. The correction factors for colchicoside and 3-Odemethylcolchicine were also determined and validated, resulting in a correction factor of 1.94 and 1.20, respectively. By using these correction factors, the individual constituents in the crude extract could be quantified; it contained 1.46% colchicoside and 1.27% 3-O-demethylcolchicine. Different batches of extract contained different amounts of colchicine and colchicine derivatives. This emphasizes the importance of quality/batch control and the use of quantified / standardized extracts. Even though the starting plant material of each batch is the same, variations in extraction lead to small differences in content. The level of plant constituents is influenced by different parameters, e.g. seasonal variation, location, time of harvest. Therefore, it is important to have a validated analytical method to determine the quantity of each compound in each batch of plant material/extract that is biologically evaluated.
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Experimental
General experimental procedures: All solvents were purchased from either Acros Organics (Geel, Belgium) or Fisher Scientific (Leicestershire, UK) and were at least analytical grade. All reagents were purchased from Acros Organics or Sigma-Aldrich (St. Louis, MO, USA). Solvents used for HPLC, i.e. methanol (MeOH) and acetonitrile were HPLC grade and purchased from Fisher Scientific. RiOS water was prepared by reverse osmosis and water for HPLC was dispensed by a Milli-Q system from Millipore (Bedford, MA, USA) and passed through a 0.22 μm membrane filter. The reference material, colchicine (97%), was purchased from Sigma-Aldrich.
High performance liquid chromatography (HPLC):
An Agilent 1200 series high performance liquid chromatography system with degasser, quaternary pump, automatic injection sampler, thermostatic column compartment and a diode array detector (DAD) (Agilent Technologies, Eindhoven, The Netherlands) was used. Different silica-based columns were used such as Apollo C18 (250 x 4.6 mm, 5 µm) (Grace, Columbia, MD, USA) and a Phenomenex Luna C18 (2) (250 x 4.6 mm, 5 µm) (Phenomenex, Torrance, CA, USA). A suitable precolumn was also installed to ensure the lifetime of the columns.
Semi-preparative high performance liquid chromatography:
A semi-preparative HPLC (Waters, Milford, MA, USA) with a binary pump, automatic injection sampler, photo diode array detector, triple quadrupole mass spectrometer (TQD-MS) and an automatic fraction collector was used to isolate reference material. A Phenomenex Luna 5 µm C 18 (2) 100 Å column with larger internal diameter (250 x 10 mm) was used.
Nuclear magnetic resonance (NMR) spectroscopy: NMR spectra were recorded on a Bruker DRX-400 instrument (Rheinstetten, Germany), operating at 400 MHz for 1 H and at 100 MHz for 13 C, employing either a 3 mm broadband inverse (BBI) probe or a 5-mm dual 1 H/ 13 C probe using standard Bruker pulse sequences.
Mass spectrometry (MS):
Mass spectra were recorded on a LC-MS system consisting of an Acquity ultra performance liquid chromatograph (UPLC), with an autosampler and a binary pump (Waters, Milford, MA, USA), and equipped with a 10 µL loop. The UPLC system was coupled to a triple quadrupole mass spectrometer (Waters, Milford, MA, USA) equipped with an electrospray ionization (ESI) source operated in the positive ion mode to record the mass spectrum of the individual compounds. MS conditions were as follows: capillary voltage 3.4 kV, extractor voltage 2 V, cone voltage 30 V, source temperature 150°C, desolvation temperature 450°C, RF lens 0.1 V, desolvation gas flow 950 L/h, cone gas flow 50 L/h. Compounds were separated on an Acquity HSS C 18 column (2.1 x 100 mm, 1.8 µm) also from Waters. The column was maintained at a temperature of 30°C. The flow rate was set at 0.5 mL and the mobile phases were (A) water and (B) acetonitrile. The used gradient was 0 min, 10% B; 1 min, 10% B; 5 min, 40% B; 7.5 min, 100% B; 10 min, 100% B; 2.5 µL was injected using a partial loop with needle overfill injection. All data were recorded and processed using Masslynx software, version 4.1 (Waters).
Plant material: Gloriosa superba L. seeds were kindly provided by Indena (Milano, Italy) (batch n° C140020) and were obtained in February 2011. A certificate of analysis n° 11/0208/LSP was included.
Extraction and identification of the main compounds:
The seeds of G. superba were dried for an extra 2 weeks in an oven at a temperature of 45°C. The seeds were then ground and sieved through a 2 mm sieve. The ground seeds (5.3 kg) were extracted exhaustively and consecutively by percolation and maceration with 95 L of 80% ethanol at room temperature. Ethanol was removed under reduced pressure at 40°C and the aqueous extract was lyophilized. The yield of crude extract was 846.7 g. The 3 main compounds, colchicoside, 3-O-demethylcolchicine, and colchicine were isolated and identified by NMR and MS.
Semi-preparative isolation of the two colchicine derivatives:
Colchicoside and 3-O-demethylcolchicine were isolated from the crude extract using semi-preparative HPLC coupled to a mass spectrometer and a diode array detector, and an automatic fraction collector. A concentration of about 25 -30 mg/mL in MeOH of the crude extract was prepared and 1500 -1800 µL of this solution was injected, after filtration. For this purpose a Phenomenex Luna 5 µm C 18 100 Å column with larger internal diameter (250 x 10 mm) was used. The mobile phase and gradient were kept the same as for the analytical method. The flow rate was increased to 3.0 mL/min and the make-up pump (with an 80% MeOH/ 20% H 2 O/ 0.1% formic acid solution) was set at 0.5 mL/min. The collection was triggered by mass m/z 386 and the 2 peaks were consecutively collected. To investigate the purity, the isolated compounds were injected at a high concentration (0.1 mg/mL for colchicoside and 0.4 mg/mL for 3-O-demethylcolchicine) in the HPLC (Agilent 1200). The chromatogram was investigated at different wavelengths, and no extra peaks were present at a wavelength different from 245 nm. All peaks that did not appear in the blank run were integrated and the area percentage of the isolated compounds was calculated. The percentage of purity was calculated by means of the normalization method and was 97% for colchicoside and 99% for 3-Odemethylcolchicine.
Colchicine-poor / colchicoside-rich extract: Liquid-liquid partition was performed according to the literature, with some modifications [10, 16, 17] . About 50 g of the crude dry extract was dissolved in 300 mL 5% acetic acid (pH 2.37). This solution was extracted 3 times with 300 mL diethyl ether. Afterwards, the aqueous fraction was extracted 3 times with 300 mL methylene chloride. This latter aqueous fraction was then analyzed by HPLC. Mobile phase A was water with 0.05% TFA and mobile phase B was acetonitrile. The flow rate was set at 1.0 mL/min and the DAD was set at a wavelength of 350 nm. The gradient used was 0 min, 5% B; 5 min, 5% B; 60 min, 100% B. This fraction contained mostly colchicoside and 3-O-demethylcolchicine and less colchicine, as intended.
Analytical method
Reference solution: About 25 mg of colchicine (97% purity) was accurately weighed into a measuring flask (50.0 mL). This material was dissolved in 50% MeOH and ultrasonicated for 15 min. After cooling, this solution was diluted 12.5, 50, and 250 times resulting in concentrations of 0.04, 0.01 and 0.002 mg/mL, respectively.
Test solution:
About 100 mg of G. superba extract was accurately weighed into a measuring flask of 20.0 mL. It was dissolved in MeOH and ultrasonicated for 15 min. After cooling down, 5.0 mL of this solution was transferred into a measuring flask of 25.0 mL. Five mL of water was added to the same flask and filled up with 50% MeOH, after cooling down.
HPLC conditions:
The reference and test solutions were analyzed by means of HPLC by injecting 20 µL. The following gradient was used with mobile phase A being water and B acetonitrile: 0 min, 10% B; 5 min, 10% B; 25 min, 40% B; 35 min, 100% B; 40 min, 100% B. The column used was a Phenomenex Luna 5 µm C18 100 Å (250 x 4.6 mm) with a flow rate of 1.0 mL/min. The peaks were detected at 245 nm.
Validation:
The method was validated according to the ICH guidelines [14, 18] . The calibration model, range, linearity, precision, accuracy, and specificity were investigated.
For the calibration model of colchicine 10 solutions of different concentrations were prepared from a stock solution. This stock solution was prepared by dissolving 26.2 mg of colchicine standard with a purity of 97% in 50.0 mL 50% MeOH and diluting it 5 times with 50% MeOH. The concentrations of the solutions ranged from 0.0021 mg/mL to 0.0419 mg/mL, and each solution was injected twice.
For the repeatability, 6 separate samples were analyzed on the same day. Every sample was injected once. For the intermediate precision on different days, 6 separate samples (100% or 100 mg) were analyzed on the same day, and this was repeated on 2 consecutive days. Every sample was injected once. For the intermediate precision of different concentration levels 6 samples with half the amount (50% or 50 mg) and 6 samples with higher amount (150% or 150 mg) were analyzed. The reference solutions for the calibration curve used to determine the amount of colchicine were freshly prepared each day, and also injected at the beginning and at the end of the sequence.
The accuracy for colchicine was investigated using the standard addition method, and was tested on at least 3 concentration levels in triplicate. The standard addition experiment was performed by spiking different amounts of colchicine standard to 50% of the crude extract until a total concentration of 75%, 100%, and 125% of colchicine was obtained. For each sample, about 50 mg of the crude extract was weighed in a measuring flask (20.0 mL). A stock solution of colchicine in MeOH at a concentration of 0.263 mg/mL was prepared, and 3.0, 6.0 and 9.0 mL samples of this solution were added to the crude extract. This mixture was further dissolved in MeOH and ultrasonicated for 15 min. After cooling down, the samples were diluted 5 times with 50% MeOH. The samples at the different concentration levels were prepared in triplicate, and each sample was injected once.
The specificity of the method was determined by investigating the peak purity of the 3 alkaloids (colchicoside, 3-O-demethylcolchicine, and colchicine) in the crude extract by using HPLC-DAD.
Correction factor
Firstly, the linearity of colchicoside and 3-O-demethylcolchicine was investigated. Ten solutions at different concentrations were prepared from a stock solution of 0.11 mg/mL and 0.10 mg/mL, respectively. The concentration range for colchicoside and 3-Odemethylcolchicine was from 0.002 to 0.04 mg/mL. Afterwards, the precision of the correction factor for the response was determined.
For the determination and validation of the correction factor both primary standard (colchicoside and 3-O-demethylcolchicine) and secondary standard (colchicine) were injected on 3 different days.
On day 1, a standard solution was prepared containing the primary and secondary standards in a concentration of 100%. On day 2, a standard solution was prepared containing the primary standard at the lowest level of the linearity range and the secondary standard in a concentration of 100%. On day 3, a standard solution was prepared containing the primary standard at the highest level of the linearity range and the secondary standard in a concentration of 100%. Fresh solutions were prepared daily and every solution was injected 6 times.
